Regeneron Pharmaceuticals Statistics
Share Statistics
Regeneron Pharmaceuticals has 108.07M shares outstanding. The number of shares has increased by 0.12% in one year.
| Shares Outstanding | 108.07M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -0.32% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 105.92M |
| Failed to Deliver (FTD) Shares | 58 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 1.88M, so 1.74% of the outstanding shares have been sold short.
| Short Interest | 1.88M |
| Short % of Shares Out | 1.74% |
| Short % of Float | 1.77% |
| Short Ratio (days to cover) | 2.14 |
Valuation Ratios
The PE ratio is 23.7 and the forward PE ratio is 18.12. Regeneron Pharmaceuticals 's PEG ratio is 0.37.
| PE Ratio | 23.7 |
| Forward PE | 18.12 |
| PS Ratio | 7.14 |
| Forward PS | 4.8 |
| PB Ratio | 3.61 |
| P/FCF Ratio | 25.55 |
| PEG Ratio | 0.37 |
Enterprise Valuation
Regeneron Pharmaceuticals Inc. has an Enterprise Value (EV) of 93.69B.
| EV / Earnings | 23.7 |
| EV / Sales | 7.14 |
| EV / EBITDA | 19.96 |
| EV / EBIT | 23.15 |
| EV / FCF | 25.54 |
Financial Position
The company has a current ratio of 5.69, with a Debt / Equity ratio of 0.08.
| Current Ratio | 5.69 |
| Quick Ratio | 4.94 |
| Debt / Equity | 0.08 |
| Total Debt / Capitalization | 7.09 |
| Cash Flow / Debt | 2.32 |
| Interest Coverage | 55.44 |
Financial Efficiency
Return on equity (ROE) is 0.15% and return on capital (ROIC) is 13.29%.
| Return on Equity (ROE) | 0.15% |
| Return on Assets (ROA) | 0.12% |
| Return on Capital (ROIC) | 13.29% |
| Revenue Per Employee | 926.03K |
| Profits Per Employee | 279.11K |
| Employee Count | 14.16K |
| Asset Turnover | 0.4 |
| Inventory Turnover | 0.7 |
Taxes
| Income Tax | 245.70M |
| Effective Tax Rate | 0.06 |
Stock Price Statistics
The stock price has increased by -26.36% in the last 52 weeks. The beta is 0.14, so Regeneron Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 0.14 |
| 52-Week Price Change | -26.36% |
| 50-Day Moving Average | 754.9 |
| 200-Day Moving Average | 963.43 |
| Relative Strength Index (RSI) | 36.84 |
| Average Volume (20 Days) | 847.10K |
Income Statement
In the last 12 months, Regeneron Pharmaceuticals had revenue of 13.12B and earned 3.95B in profits. Earnings per share was 37.05.
| Revenue | 13.12B |
| Gross Profit | 11.30B |
| Operating Income | 4.05B |
| Net Income | 3.95B |
| EBITDA | 4.69B |
| EBIT | 4.05B |
| Earnings Per Share (EPS) | 37.05 |
Balance Sheet
The company has 2.73B in cash and 2.70B in debt, giving a net cash position of 27.10M.
| Cash & Cash Equivalents | 2.73B |
| Total Debt | 2.70B |
| Net Cash | 27.10M |
| Retained Earnings | 27.26B |
| Total Assets | 37.44B |
| Working Capital | 15.67B |
Cash Flow
In the last 12 months, operating cash flow was 4.59B and capital expenditures -926.40M, giving a free cash flow of 3.67B.
| Operating Cash Flow | 4.59B |
| Capital Expenditures | -926.40M |
| Free Cash Flow | 3.67B |
| FCF Per Share | 34.37 |
Margins
Gross margin is 86.16%, with operating and profit margins of 30.85% and 30.14%.
| Gross Margin | 86.16% |
| Operating Margin | 30.85% |
| Pretax Margin | 32.01% |
| Profit Margin | 30.14% |
| EBITDA Margin | 35.78% |
| EBIT Margin | 30.85% |
| FCF Margin | 27.96% |
Dividends & Yields
REGN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 5.37% |
| FCF Yield | 4.92% |
Analyst Forecast
The average price target for REGN is $1150, which is 66.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $1150 |
| Price Target Difference | 66.6% |
| Analyst Consensus | Buy |
| Analyst Count | 21 |
Scores
| Altman Z-Score | 8.13 |
| Piotroski F-Score | 4 |